Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.
You may also be interested in...
The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.
AstraZeneca's Lynparza, Tesaro's Zejula and Clovis' Rubraca have brought much needed advances to patients with ovarian cancer, but the market is relatively small and the competition intense, while unmet need remains high.
AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.